Header2

ADVANCED THERAPY IN INFLAMMATORY BOWEL DISEASE, 3rd edition Vol 1

ISBN: 978-1-60795-034-9

Bayless_ibd_-_vol_1

Price
$99.95

 

November 2011 (Volume 1: Ulcerative Colitis)
November 2011 (Volume 2: Crohn’s Disease)
1000 pages/casebound
ISBN 978-1-60795-034-9 (Vol. 1)
ISBN 978-1-60795-035-6 (Vol. 2)
TO PURCHASE VOLUME 2, visit
http://www.pmph-usa.com/products/advanced-therapy-in-inflammatory-bowel-disease-3rd-edition-vol-2
US $99.95 (each volume)
 
Theodore M. Bayless, MD
Sherlock Hibbs Professor of Inflammatory Bowel Disease and
Director Emeritus
Meyerhoff IBD Center
Johns Hopkins University School of Medicine
Baltimore, Maryland                  
 
Stephen B. Hanauer, MD
Joseph B. Kirsner Professor of Medicine and Clinical Pharmacology
Director of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medical Center
Chicago, Illinois
 
Now published in two volumes to accommodate new chapters on the many advances in understanding and treatment options, this set of volumes represents the definitive reference on inflammatory bowel disease, a spectrum of diseases that is receiving increasing attention as our understanding of the etiological factors increases and diagnostic tools are refined. Basic research accelerated at the beginning of this decade and is now yielding new, more targeted treatments than were available just a few years ago.
 
Volume 1 is on IBD and Ulcerative Colitis, and Volume 2 is on IBD and Crohn’s Disease. All areas that were covered in the 2nd edition have been expanded and updated. New sections include the rapidly expanding knowledge of genetics and the role of the intestinal flora and environmental factors in etiology and pathogenesis. Among the 168 chapters, there are 20 on biologic therapies and 30 on surgical management. The consultant/authors clearly state their approach to important issues, such as the duration of immunomodulator and of anti-TNF-α use and the options for managing isolated low-grade dysplasia. A strong focus on the individual patient is woven throughout both volumes, including the benefits and risks of potentially life-altering therapies and surgeries. Entire sections detail concerns about the well-being of each person. This book provides information for health professionals who help both pediatric and adult patients navigate through the lifelong shadow of a chronic, probably genetically determined ordeal.
 
KEY FEATURES  
·         The most comprehensive textbook on IBD available
·         Dynamic website with linking to journal articles, downloadable chapters, and image databank
·         Includes 200 photographs, and many supplemental diagrams and tables
·         Detailed Table of Contents highlights important concepts
·         Full color throughout both volumes
 
CONTENTS
Contents for both volumes are listed below. The TOC for Volume 2 begins at Chapter 99 and is highlighted in blue
 
VOLUME 1: ULCERATIVE COLITIS
INTRODUCTION
1.       Expectations for the Patient with Ulcerative Colitis: Dana C. Moffatt, MD; Charles N. Bernstein MD
2.       Expectations for the Patient with Crohn’s Disease: Faten N. Aberra, MD, MSCE; James D. Lewis, MD, MSCE
3.       Living with Ulcerative Colitis: Richard Rood, MD
4.       Living with Crohn‘s Disease: Erien Matagrano, MD
5.       Pediatric Patient, Family, Doctor Interactions: Lana Hattar, MD; George D. Ferry, MD
6.       Dealing with Teenagers with IBD: Melvin B. Heyman, MD
7.       Psychosocial Concomitants of Pediatric Inflammatory Bowel Disease: Stanley A. Cohen, MD; Sobba P. Fritz, PhD
8.       Recognizing and Managing Patients’ Concerns: Douglas R. Drossman, MD; Hans Herfarth, PhD
9.   Benefits of Enhancing the Patient-Medical Interface: Raymond K. Cross, MD                                                                                
ETIOLOGY AND PATHOPHYSIOLOGY OF IBD
10. IBD Pathogenesis: Current Concepts. Oren Shibolet, MD; Daniel K. Podolsky, MD
11. IBD Genetics: Potential Clinical Relevance: Steven R. Brant, MD
12Effect of Age at Onset on the IBD Phenotypes and Genotypes: Subra Kugathasen, MD; Clifton Huang, MD
13. Environmental influences in IBD: Justina Sam, MD; Geoffrey C. Nguyen, MD
14. Biological Therapy in IBD: Charles Wang, MD; Lloyd Mayer, MD
15. Addressable Pathophysiologic Alterations in the IBD Patient: Mark T. Worthington, MD, AGA
16. Exploring the Links Between Inflammation and Neoplasia in IBD: Preetika Sinh, MD; Terrance Barrett, MD
 
DIAGNOSTIC/PROGNOSTIC METHODOLOG
17. Clinical Subtypes: Morten H. Vatn, MD
18. Computer Database for Patients with IBD: Jacques Cosnes, MD; P Seksik, MD
19. Clinical Measures of Disease Activity: Brian Feagan, MD
20. Useful Biologic Markers as Activity Indices:Severine Vermeire, MD, PhD; Gert Van Assche, MD, PhD; Paul Rutgeerts, MD, PhD, FRCP, ACAG
21. Serologic Markers for Diagnosis and Prognosis: Dermott McGovern, MD
22. Clinical Utility of Quality of Life Measurements: Shveta S. Motwani, MD; E. Jan Irvine, MD, FRCPC, MSc
23. Endoscopy in IBD: Pieter C.F. Stokkers; Evelien Dekker; Paul Fockens
24. Magnifying Colonoscopy in IBD Patients: S. Kudo
25.    Endoscopic Biopses: Karel Geboes, MD; Gert De Hertogh, MD
26.    Crohn’s Disease: CT Scanning in Clinical Decision-Making:Karen M. Horton, MD; Elliot K. Fishman, MD
27.    CT Enterography and Small Bowel Imaging: Edward Loftus, MD
28.    PET/CT and Nuclear Imaging of Inflammation: Heather A. Jacene, MD, Richard L. Wahl, MD
29.    Video Capsule Endoscopy and Inflammatory Bowel Disease: David R. Cave, MD, PhD
30.    Transabdominal Bowel Sonography in Clinical Decision-making: Christoph Gasche, MD
31.    Imaging Options in Perianal Crohn’s Disease: David A. Schwartz, MD; Sara N. Horst, MD
 
AGGRAVATING FACTORS IN THE IBD PATIENT:
32.    IBD and Stress: Yvette Leung, MD, FRCPC; Lloyd R. Sutherland, MD, MSc, FRCPC, FACP
33.    “Refractory” IBD: David Sachar, MD; Dr. Ellis
34.    Infectious Agents as Aggravating Factors in Inflammatory Bowel Disease: Christina M. Surawicz, MD; Kabir Julka, MD
35.    EBV, CMV, JC Viruses et al. Complicating IBD: Akin Inderson, MD; Daniel W. Hommes, MD
36.    Clostridium difficile and Inflammatory Bowel Disease: Ashwin N. Ananthakrishnan, MD, MPH; David G. Binion, MD
37.    Nonsteroidal Anti-Inflammatory Drugs and IBD: Guy Sisson, MRCP; Ken Takeuchi, MD, PhD; Ingvar Bjarnason, MD, MSc, FRCPath, FRCP, DSc
38.    Smoking and Crohn’s Disease: Michael F. Picco, MD, PhD
39.    Lessing Dietary Symptoms in IBS and IBD Patients: Peter R. Gibson, MD; Susan J. Shepherd
40.    Post-inflammatory IBS: Stephen Collins, MD
41.    Managing IBS and IBD in the Same Individual: Phillip M. Ginsburg, MD; Richard P. MacDermott, MD; Theodore M. Bayless, MD
42.    Adverse Influences of Pregnancy on IBD Patients: Alan C. Moss, MD; Jacqueline L. Wolf, MD
 
MEDICAL THERAPY OF IBD
43.    Pharmacogenomics in IBD: Raja Affendi Raha Ali, MB, MMedSc, MRCPI, MRCP, HDip; Laurence J. Egan, MD, FRCPI
44.    Placebo Responses in IBD: Gary Lichtenstein, MD; Wojciech Blonski, MD
45.    Adherence Issues in the Management of IBD: Sunanda Kane, MD
46.    Modes of Action of Anti-Inflammatory and Immunomodulator Medications. Matthew Grisham, MD
47.    Approaches That Alter Luminal Contents and Bacterial Action: Fergus Shanahan, MD
48.    Use of Nicotine and Tobacco in Ulcerative Colitis: Amir Karban, MD
49.    Genetic Counseling: David Rubin, MD; S. A. Cummings, MD
 
ULCERATIVE COLITIS
50.    Management of Distal Colitis and Rectal Symptoms: Maria Abreu, MD
51.    Mucosal Repair and Protection Approaches to Therapy: Joshua Korsznik, MD; Sreedhar Subramanian, MD
52.    Dietary Induced symptoms in IBD patients: Sheila Crowe, MD
53.    Refractory Distal Colitis, Including Topical Immunomodulator Therapy. Philip B. Miner, Jr., MD
54.    Sequential and Combination Therapy of Ulcerative Colitis: William J. Tremaine, MD
55.    Predicting Relapses in Ulcerative Colitis: Mark Peppercorn, MD; Alain Bitton, MD
56.    Aminosalicylate Therapy for Ulcerative Colitis: Steven B. Hanauer, MD
57.    Systemic Corticosteroids in Ulcerative Colitis: Miles Sparrow, MD
58.    Steroid Unresponsiveness in Inflammatory Bowel Disease: Alan Moss, MD                                                                                                                                   
59.    Immunomodulators in Ulcerative Colitis: Daniel Present, MD; Mark Lazarav, MD
60.    Methotrexate Use in Ulcerative Colitis: Richard Kozarek, MD
61.    Anti-TNF Use in Ulcerative Colitis: Bruce Sands, MD
62.    Management of Severe Ulcerative Colitis: Asher Kornbluth, MD
63.    Use of Antibiotics in Ulcerative Colitis:Phillip Marteau, MD
64.    Management of Ulcerative Colitis in Children : Maria Oliva-Hemker, MD
65.    Apharesis Use in IBD: Stephen B. Hanauer, MD
66.    Indeterminate Colitis: Hillary A. Steinhart, MD
67.    Potential New Therapies in Ulcerative Colitis: Stefan Schreiber, MD
 
SURGERY FOR ULCERATIVE COLITIS
68. Indications for Surgery, Choice of Procedures, and Expected Resuls: Robin Mcleod, MD
69. Brooke Ileostomy: Walter Kolturn, MD
70. Ileoanal Pouch Anastomosis: Victor W. Fazio, MD; Myles Joyce, MD
71. Long-Term Results with Ileoanal pouch: John H. Pemberton, MD
72. Managing the IBD Ostomy patient: Jan Colwell, MD
73. Endoscopy in Evaluating Ileal Pouches: Jerome D. Waye, MD
74. Role of the Pathologist in Evaluating Chronic Pouches: Robert E. Petras, MD
75. Pouch Dysfunction and Complications: Bo Shen, MD
76. Probiotics in Pouchitis and Ulcerative Colitis: Richard A. Fedorak, MD
77. Ileoanal Pouch Surgery in Childhood: Donald Liu, MD
78. Ileorectal Anastomosis: Susan DeMeester Gearhart, MD
79. Indeterminate Colitis: Surgical Approaches: Neil Mortensen, MD
 
COMPLICATIONS OF INFLAMMATORY BOWEL DISEASE
80. Lymphoma Risks in IBD: Harry Sokol, MD; Laurent Beaugerie, MD
81. Dysplasia Surveillance Programs: Anita Afzali, MD; Teresa A. Brentnall, MD
82. Enhanced Visualization Techniques for Dysplasia Cancer Detection: Themistocles
      Dassopoulos, MD; Melissa Munsell, MD
83. Cancer Prevention Strategies in Inflammatory Bowel Disease: Vera Kandror Denmark, MD; Thomas A. Ullman, MD
84. Dysplasia Surveillance in Crohn’s Disease: Peter H. Rubin, MD
85. Extra-intestinal Manifestations of IBD: Ioannis Oikonomou, MD; Kiron M. Das, MD, PhD, FRCP
86. Cutaneous Manifestations of IBD: Jeff Callen, MD
87. Ocular Manifestations of IBD: James P. Dunn, MD
88. Arthritis Associated with Inflammatory Bowel Disease: Timothy R. Orchard, MD, DM, FRCP; David G. Walker MRCP
89. Lessons from Treatment of Rheumatoid Arthritis:  Ulf Muller-Ladner, MD; Jurgen Scholmerich, MD
90. Metabolic Bone Disease in IBD Patients:Prevention and Treatment: Edward Loftus, MD
91. Osteonecrosis (Ischemic Necrosis) in IBD: Hugh J. Freeman, MD
92. Hyperoxaluria and Nephrolithiasis: Joseph H. Sellin, MD; Selvi Thirumurthi, MD
93. Sclerosing Cholangitis and Cholangiocarcinoma in IBD Patients: Kevin D. Lindor MD
94. Stricture Management and Detecting Cholangiocarcinoma in Primary Sclerosing
        Cholangitis: Sanjay Jaganath, MD; Devi Mukkai Krishnamurty, MBBS
95. Liver Transplantation for Primary Sclerosing Cholangitis: Wilhem J.S. de Villers, MD
96. Iron Deficiency, Hematologic Problems and Thrombosis in IBD: Ashwin N. Ananthakrishnan, MD, MPH; David G. Binion, MD
97. Pancreatic Dysfunction in IBD: Robert J. Bonasera MD; James H. Grendell, MD
98. Radiation Exposure in IBD Patients: Richard N. Fedorak, MD; Karen L. Krocker, MD
 
VOLUME 2: IBD AND CROHN’S DISEASE
CROHN’S DISEASE THERAPY
99.   Crohn’s Disease: Therapeutic Implications of Disease Subtypes: Stephen Targan
100. Mucosal Healing in IBD: Essential or Cosmetics?: Peter Bessuyt, MD; Geert D’Haens MD
101. Sequential and Combination Therapy for Small Bowel Disease: Christian D. Stone, MD
102. Results and Patient Selection for Early Use of immunomodulators and Anti-
        TNF Agents (“Top Down”): Marc Lemann, MD.
103. The Role of Mesalamine in Crohn’s Disease: Alessandro Armuzzi, MD; Cosimo Prantera, MD
104. Altering Luminal Contents in Crohn’s Disease: R. Balfour Sartor, MD
105. Topically Active Steroid Preparations: John K. Marshall, MD
106. Azathioprine and 6-Mercaptopurine for Treatment of Crohn’s Disease: Burton I. Korelitz, MD
107. Optimizing Azathioprine and 6-Mercaptopurine Use in IBD, Including Allopurinol: Carmen Cuffari, MD
108. Methotrexate in Inflammatory Bowel Disease: Brian Feagan, MD
109. Cyclosporine and Tacrolimus in the Treatment of Crohn’s Disease: Simon Lichtiger, MD; Jenny Souk, MD
110. De Novo Anti-TNF Therapy in Crohn’s Disease: Evidence-Based Results and Clinical Experience: Stephen B. Hanauer, MD
111. Switching Anti-TNF Agents: Evidenced-Based Results and Clinical Experience: R. Panicione, MD
112. Optimizing Anti-TNF Therapy in IBD: Scott D. Lee, MD; Dr. Harper
113. Experience with long term anti-TNF therapy: Miguel Reguerio, MD  
114. The Duration of Use of Immunomodulators and Biologics in Crohn’s Disease: Russell D. Cohen, MD
115. Clinical Experience with Adhesion Molecule Inhibitors: Brian C. Fegan, MD
116. Pediatric Therapies in Inflammatory Bowel Disease: Judith Kelsen, MD; Anna Hunter, MD.; Robert N. Baldesano, MD
117. Influences of Hepatosplenic T-Cell Lymphoma on Management Decisions: Jeffrey S. Hyams, MD
118. Balancing Benefits and Risks of Biologic Therapies: Corey A. Siegel, MD
119.  Perianal Fistula Management: David A. Schwartz, MD
120. An Evidenced-Based Guide to Applying Integrated Medicine for the IBD Patient: John O. Clarke, MD; Laura K. Turnbull, MSN; Joyce M. Koh, MD; S. Devi Rampertob, MD; Gerald Mullin, MD
121. Stem Cell Transplant in Unresponsive Patients: Robert M. Craig, MD
122. Bowel Rest, Enteral and Parenteral Nutrition in IBD Patients: Rosemarie L. Fisher, MD; Jason Hemming, MD
123. Enteral Nutrition: Impact on Disease Activity and Growth in Pediatric Inflammatory Bowel Disease: Anne M. Griffiths, MD; Mary E. Sherlock, MRCP
124. Gastroduodenal Crohn’s Disease: Robert Burakoff, MD
125. Crohn’s Jejunoileitis: Kim L. Issacas, MD
126. Fistulizing and Perforating Crohn’s Disease: Richard P. MacDermott, MD
127. Dysplasia Surviellance in Crohn’s Disease: Peter Rubin, MD
128. Small Bowel Stenosis in Crohn’d Disease: John Kwon, MD; Theodore M. Bayless, MD
129. Colonic Strictures in Crohn’s Disease Patients: Keely Parisian,
         MD; Bret A. Lashner, MD
130. The Role of Enteroscopy in the Evaluation and Treatment of Crohn’s Disease Small bowel strictures: Patrick I. Okolo III, MD; Lissette Musaib Ali, MD
131. Endoscopic Treatment of Crohn’s Primary and Anastomotic Stenosis: Richard A. Kozorek, MD
 
SURGERY FOR CROHN’S DISEASE
132. Indications and Procedures for Surgery for Small Bowel Crohn’s Disease: Fabrizio Michelasi, MD; Sharon L. Stein, MD
133. IBD Surgery in Pediatric Patients: Cathy E. Shin, MD
134. Perioperative Nutrition Support: Michael D. Sitrin, MD; Vishal Bhagat, MD
135. Laparoscopic Resection for Crohn’s Disease: Hien T. Nguyen, MD; Anne Lidor, MD
136. Management of Obstructed Crohn’s Disease Patient: Michael Marohn, MD
137. Strictureplasty Surgery for Crohn’s Disease: Scott A. Strong, MD
138. Gastroduodenal Crohn’s Disease: Surgical Management: Jeffrey Milson, MD
139. Intra-Abdominal Abscesses in Crohn’s Disease. Peter D. R. Higgins, MD; Akbar K. Waljee, MD; Ryan J. Stidham, MD
140. Measures to Minimize Postoperative Recurrences of Crohn’s Disease Paul J. Rutgeerts, MD
141. Diarrhea Following Small Bowel Resection: Lawrence R. Schiller, MD
142. Clinical Management of Short-Bowel Syndrome: Alan L. Bucchman, MD
143. Intestinal Transplantation: Thomas M. Fishbein, MD; Juan Francisco Guerra, MD
144. Management of Abdominal Fistulae: Howard Kaufman, MD; Patrizio Petrone, MD
145. Surgery for Crohn’s Colitis: Elizabeth Wick, MD; Genevieve B. Melton, MD
146. Perianal Disease: Jason Bodzin, MD
147. Rectovaginal Fistulae: Tracy L. Hull, MD;
 
PATIENT SUPPORT SERVICES
148. Nurse Practioner in GI: Sharon Dudley-Brown, MRCP
149. Patient Advocacy In IBD Treatment: Lisa Turnbough, RN; Donna Rode, AA
150. Crohn’s and Colitis Foundation of America: Information and Support Services: Kim Frederick, LCSW, MSW
151. Pediatric Patient and Family Support:  Maria I. Clavell, MD; Robert D. Baker, MD; Susan S. Baker, MD
152. Insurance and Disability Advocacy Issues in IBD: Douglas C. Wolf, MD
153. Sexual Adjustments and Body Image: Paula Erwin-Toth, MSN, RN
 
BEHAVIORAL THERAPY
154. Psychiatric Complications of IBD: Glenn Triesman, MD
155. Psychosocial Concomitants of Pediatric Inflammatory Bowel Disease: Stanley Cohen, MD; Sobha P. Fritz, PhD
156. Psychological Perspectives on the Care of Patients with IBD: David Edwin, PhD
157. Coping Strategies in IBS and IBD Patients: Michael P. Jones
158. Stress Management and Relaxation Training: H. Richard Waranch, PhD
159. Abdominal Pain Management: Michael Kaminsky, PhD
160. Fitness and Exercise Program for IBD Patients. Peter Nielson
161. Complementary and Alternative Medicine in Inflammatory Bowel Disease: Robert J. Hilsden, MD; Marja J. Verhoef, PhD
 
SPECIAL SITUATIONS
162. Fertility and Pregnancy in IBD: Uma Mahadevan, MD
163. IBD Medications in Pregnancy: Sharon Dudley-Brown, MRCP
164. Influences of Discrepancy in IBD Care: Geoffrey C. Nguyen, MD; Smita Halder, MD
165. Colitis in the Elderly: Anne Silverman, MD
166. Collagenous and Lymphocytic Colitis and Enteritis: Mark Worthington, MD; Ann Tuskey, MD
167. Chronic Immunodeficiency Syndromes Affecting the Gastrointestinal Tract: Lloyd Mayer, MD; Jimmy Ko, MD
168. Small Intestinal Transplantation: Michael Zasloff, MD
169. Behçet’s Disease: Eric Vasiklocas, MD
170. Therapy of Ulcerative Jejunoileitis: G. R. Correa, MD
171. Gastrointestinal Complications of Stem Cell Transplanation: Linda A. Lee, MD; Georgia Vogelsang, MD
172. Bone Health in IBD Patients: Charles Sninsky, MD